Literature DB >> 21157976

Hepatocellular carcinoma treated with transarterial chemoembolization: dynamic perfusion-CT in the assessment of residual tumor.

Davide Ippolito1, Pietro-Andrea Bonaffini, Laura Ratti, Laura Antolini, Rocco Corso, Ferruccio Fazio, Sandro Sironi.   

Abstract

AIM: To asses the value of computed tomography (CT)-perfusion in the detection of residual hepatocellular carcinoma (HCC) vascularization after transarterial chemoembolization (TACE).
METHODS: Thirty-two consecutive patients were prospectively included in this study. All patients had liver cirrhosis and a confirmed HCC lesion which was treated with TACE. One month after treatment, perfusion measurements of treated lesions were carried out. The CT-perfusion (CT-p) protocol was performed with 16 slice multidetector computed tomography which included the following parameters: 8 dynamic slices/scan per 40 scans after iv injection of 50 mL of iodinated contrast (350 mg/mL) at a flow rate of 6 mL/s. Treated lesions were evaluated using dedicated perfusion software, which generated a quantitative colour map of perfusion. The following parameters were considered: hepatic perfusion (HP), arterial perfusion (AP), blood volume (BV), hepatic perfusion index (HPI), and time to peak (TTP). Perfusion parameters were described with quartile values of their distribution and statistically analyzed.
RESULTS: Perfusion parameters of the treated lesions could be quantitatively assessed using CT-p analysis. The presence of residual tumor tissue was observed in 13 of the 32 patients. The values of the perfusion parameters measured within the relapse tissue were: HP (mL/100 g per minute): median = 44.4 (1(st)qt = 31.3, 3(rd)qt = 55.8); BV (mL/100 g): median = 18.7 (1(st)qt = 11.5, 3(rd)qt = 22.5); AP (mL/min): median = 39.0 (1(st)qt = 36.5, 3(rd)qt = 61.3); HPI (%): median = 34.0 (1(st)qt = 30.4, 3(rd)qt = 38.9); TTP (s): median = 17.3 (1(st)qt = 15.8, 3(rd)qt = 26.5). With the use of the univariate paired Wilcoxon signed rank test, HP, AP and HPI were shown to be significantly higher (P < 0.001) in the relapse site than in the primary lesion. The BV and TTP parameters showed a tendency to be greater and lower, respectively, in the relapse site than in the primary lesion.
CONCLUSION: In patients with HCC treated with TACE, CT-p provides measurement of flow parameters related to residual arterial structures in viable tumor, thus helping in the assessment of therapeutic response.

Entities:  

Mesh:

Year:  2010        PMID: 21157976      PMCID: PMC3007114          DOI: 10.3748/wjg.v16.i47.5993

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  20 in total

Review 1.  Perfusion CT: a worthwhile enhancement?

Authors:  K A Miles; M R Griffiths
Journal:  Br J Radiol       Date:  2003-04       Impact factor: 3.039

2.  Non-invasive quantification of liver perfusion with dynamic computed tomography and a dual-input one-compartmental model.

Authors:  R Materne; B E Van Beers; A M Smith; I Leconte; J Jamart; J P Dehoux; A Keyeux; Y Horsmans
Journal:  Clin Sci (Lond)       Date:  2000-12       Impact factor: 6.124

Review 3.  Perfusion CT for the assessment of tumour vascularity: which protocol?

Authors:  K A Miles
Journal:  Br J Radiol       Date:  2003       Impact factor: 3.039

Review 4.  Hepatocellular carcinoma treated with interventional procedures: CT and MRI follow-up.

Authors:  Yong-Song Guan; Long Sun; Xiang-Ping Zhou; Xiao Li; Xiao-Hua Zheng
Journal:  World J Gastroenterol       Date:  2004-12-15       Impact factor: 5.742

5.  Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue-long-term prospective study.

Authors:  E Caturelli; D A Siena; S Fusilli; M R Villani; G Schiavone; M Nardella; S Balzano; F Florio
Journal:  Radiology       Date:  2000-04       Impact factor: 11.105

Review 6.  Transcatheter arterial chemoembolization for hepatocellular carcinoma: anatomic and hemodynamic considerations in the hepatic artery and portal vein.

Authors:  Kwang-Hun Lee; Kyu-Bo Sung; Do-Yun Lee; Sang Joon Park; Ki Whang Kim; Jeong-Sik Yu
Journal:  Radiographics       Date:  2002 Sep-Oct       Impact factor: 5.333

7.  Quantitative perfusion map of malignant liver tumors, created from dynamic computed tomography data.

Authors:  Yoshito Tsushima; Shintaro Funabasama; Jun Aoki; Shigeru Sanada; Keigo Endo
Journal:  Acad Radiol       Date:  2004-02       Impact factor: 3.173

Review 8.  Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.

Authors:  Calogero Cammà; Filippo Schepis; Ambrogio Orlando; Maddalena Albanese; Lillian Shahied; Franco Trevisani; Pietro Andreone; Antonio Craxì; Mario Cottone
Journal:  Radiology       Date:  2002-07       Impact factor: 11.105

Review 9.  Chemoembolization of hepatocellular carcinoma.

Authors:  Douglas E Ramsey; Lily Y Kernagis; Michael C Soulen; Jean-Francois H Geschwind
Journal:  J Vasc Interv Radiol       Date:  2002-09       Impact factor: 3.464

10.  Computed tomography perfusion in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma.

Authors:  Guang Chen; Da-Qing Ma; Wen He; Bao-Feng Zhang; Li-Qin Zhao
Journal:  World J Gastroenterol       Date:  2008-10-07       Impact factor: 5.742

View more
  21 in total

1.  Quantitative assessment of tumour associated neovascularisation in patients with liver cirrhosis and hepatocellular carcinoma: role of dynamic-CT perfusion imaging.

Authors:  Davide Ippolito; Cristina Capraro; Alessandra Casiraghi; Cristina Cestari; Sandro Sironi
Journal:  Eur Radiol       Date:  2011-11-16       Impact factor: 5.315

Review 2.  Advanced imaging techniques in the therapeutic response of transarterial chemoembolization for hepatocellular carcinoma.

Authors:  Ke Yang; Xiao-Ming Zhang; Lin Yang; Hao Xu; Juan Peng
Journal:  World J Gastroenterol       Date:  2016-05-28       Impact factor: 5.742

Review 3.  New paradigm for management of hepatocellular carcinoma by imaging.

Authors:  Ijin Joo; Byung Ihn Choi
Journal:  Liver Cancer       Date:  2012-09       Impact factor: 11.740

Review 4.  Recent Advances in CT and MR Imaging for Evaluation of Hepatocellular Carcinoma.

Authors:  Jeong Min Lee; Jeong-Hee Yoon; Ijin Joo; Hyun Sik Woo
Journal:  Liver Cancer       Date:  2012-06       Impact factor: 11.740

5.  Clinical and prognostic value of CT perfusion imaging parameters in patients with primary liver cancer after therapy.

Authors:  Yiming Li; Yuzhou Li; Yuan Sui; Guangyao Lin; Wenqi Huang; Yinshi Zheng
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

Review 6.  CT perfusion of the liver: principles and applications in oncology.

Authors:  Se Hyung Kim; Aya Kamaya; Jürgen K Willmann
Journal:  Radiology       Date:  2014-08       Impact factor: 11.105

7.  Computed Tomography Perfusion Imaging for the Diagnosis of Hepatic Alveolar Echinococcosis.

Authors:  Recep Sade; Mecit Kantarci; Berhan Genc; Hayri Ogul; Betul Gundogdu; Omer Yilmaz
Journal:  Eurasian J Med       Date:  2017-12-29

Review 8.  Functional imaging techniques in hepatocellular carcinoma.

Authors:  V Goh; D Sarker; S Osmany; G J R Cook
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-21       Impact factor: 10.057

9.  Computed Tomography (CT) Perfusion in Abdominal Cancer: Technical Aspects.

Authors:  Martin Lundsgaard Hansen; Rikke Norling; Carsten Lauridsen; Eva Fallentin; Lene Bæksgaard; Klaus Fuglsang Kofoed; Lars Bo Svendsen; Michael Bachmann Nielsen
Journal:  Diagnostics (Basel)       Date:  2013-04-03

10.  Assessment of blood flow in hepatocellular carcinoma: correlations of computed tomography perfusion imaging and circulating angiogenic factors.

Authors:  Ya-Wen Chen; Huay-Ben Pan; Hui-Hwa Tseng; Yu-Ting Hung; Jer-Shyung Huang; Chen-Pin Chou
Journal:  Int J Mol Sci       Date:  2013-08-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.